Corline Biomedical AB (CLBIO) — Capital Reinvestment Ratio
Corline Biomedical AB (CLBIO) has a Capital Reinvestment Ratio of 0.80x as of March 2024, meaning it reinvests 1% of its operating cash flow (Skr2.30 Million) in capital expenditures (Skr1.83 Million). See Corline Biomedical AB net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Corline Biomedical AB Capital Reinvestment Ratio (2023–2023)
This chart tracks Corline Biomedical AB's Capital Reinvestment Ratio across 1 annual periods. Check how aggressively does Corline Biomedical AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Corline Biomedical AB (2023–2023)
Year-by-year Capital Reinvestment Ratio for Corline Biomedical AB from 2023 to 2023. For live market cap and broader valuation context, see Corline Biomedical AB market capitalisation.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 11.99x | Skr886.00K | Skr10.62 Million | — |